Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   OpGen   /   Curetis 2016

Aandeel OpGen OTC:OPGN.Q, US68373L5057

Vertraagde koers (usd) Verschil Volume
1,960   0,000   (0,00%) Dagrange 0,000 - 0,000 0  

Curetis 2016

Volgen
777 Posts
Pagina: «« 1 ... 27 28 29 30 31 ... 39 »» | Laatste | Omlaag ↓
  2. [verwijderd] 5 september 2016 17:16
    quote:

    ZAYBXC schreef op 5 september 2016 16:12:

    [...]

    Ik reken:
    ((1 x 7,50) + (2 x 5))/3 = 5,833.
    Bij koers 5 nog altijd bij jou volgens eerdere bericht 7,50 gemiddeld...nieuw gemiddelde 5,833.
    Het is wel rennen achter de koers aan.
    Grapje of toch kern van/met waarheid ?
    Mijn realiteit is helaas iets minder rooskleurig.

    ((1x7,50)+(1*5,00))/2=6,25

    Uiteraard alleen als de koers de € 5 gaat raken. Anders ga ik niet verdubbelen. Voor nu een flink verlies met mijn gemiddelde van € 7,50.
  3. [verwijderd] 5 september 2016 17:19
    quote:

    ZAYBXC schreef op 5 september 2016 16:50:

    Is er een liquiditeitsverschaffer aktief in het Curetis aandeel om beweging te forceren ?
    Wie koopt/verkoopt anders zo geringe hoeveelheden gelijk 10,11,14 of 16 stuks ?
    Bank Degroof Petercam.

    Daarom neem ik van de vier "buy" adviezen alleen het advies van de Groof Petercam niet helemaal serieus.
  4. [verwijderd] 5 september 2016 17:34
    quote:

    AnalytischDenker schreef op 5 september 2016 17:19:

    [...]

    Bank Degroof Petercam.

    Daarom neem ik van de vier "buy" adviezen alleen het advies van de Groof Petercam niet helemaal serieus.
    Als je het goed vindt ga ik op mijn eigen advies af en wonderbaarlijk een stuk beter dan alle vier analisten maar ja ik heb ook geen dubbele agenda of wat anders.
    Gesloten op 5,59.

    Waar is Diegy toch ?
  5. [verwijderd] 5 september 2016 17:43
    quote:

    ZAYBXC schreef op 5 september 2016 17:34:

    [...]

    Als je het goed vindt ga ik op mijn eigen advies af en wonderbaarlijk een stuk beter dan alle vier analisten maar ja ik heb ook geen dubbele agenda of wat anders.
    Gesloten op 5,59.

    Waar is Diegy toch ?
    Ik ga ook altijd op mijn eigen advies af. Daarom staat mijn totaal portefeuille dit jaar ook op meer dan 20% rendement - met name zoals je weet door de grote bewegingen bij Delta Lloyd. Helaas is een deel van mijn droomrendement daar teniet gedaan door de neerwaartse beweging van Curetis.

    Sometimes you win, Sometimes you lose. De kunst is en blijft om die win groter te laten zijn dan die lose.
  6. [verwijderd] 6 september 2016 08:29
    Curetis to Launch Next Generation CE-IVD Unyvero Implant and Tissue Infection Application Cartridge

    - Launch follows successful completion of CE Performance Evaluation Study
    - ITI now covers 102 diagnostic targets, including 85 pathogens and 17 resistance markers

    Amsterdam, the Netherlands, and Holzgerlingen, Germany, September 6, 2016 -- Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced the successful completion of the CE Performance Evaluation study of the next generation of its Unyvero ITI Implant and Tissue Infection Application Cartridge (Unyvero ITI).

    The new Unyvero ITI comes with an extended panel and increased sensitivity. It will be launched in the third quarter of 2016 as a CE-IVD-marked product in the European direct sales and international distribution markets. Unyvero ITI is designed for the diagnosis of many types of severe infections, including prosthetic joint infections, surgical site infections, catheter-associated infections and skin and soft tissue infections.

    The next-generation cartridge now covers a total of 102 diagnostic targets: 85 of the most clinically relevant pathogenic microorganisms, including Gram positive and Gram negative bacteria, several fungi, and 17 related antibiotic resistance markers. Specifically, the next generation ITI cartridge has added a universal bacterial primer, several Candida species, various types of Streptococci, Klebsiella variicola, and other new diagnostic targets. In addition, clinical sensitivity has been significantly improved for many key pathogens. Unyvero ITI is the most comprehensive commercially available panel for this indication area in a cartridge-based sample-to-answer format. The first generation ITI Application Cartridge launched in 2014 covered a total of 80 diagnostic targets.

    Sold as a consumable running on the Curetis Unyvero System, the product analyzes many challenging and heterogeneous sample types such as fluids, tissues, swabs and others. It is the second Application Cartridge for the Unyvero System launched in 2016, following the recent launch of the BCU Blood Culture Application Cartridge.
    In the performance evaluation study, a total of 1,100 samples were tested with the next generation ITI Cartridge. These included 700 samples positive for microbial growth in the routine work-up of patients.

    Final validation results from patient samples demonstrated
    ? an overall sensitivity for all pathogens of 86.9% and
    ? an overall specificity for all pathogens of 99.2%.
    Several customer sites at renowned hospitals in Europe have already agreed to further evaluate the second generation Unyvero ITI product in their clinical routine.

    “We are excited to start marketing the new ITI Application Cartridge for our Unyvero Platform,” said Dr. Achim Plum, Chief Commercial Officer of Curetis. “Our development team has done a tremendous job and provided us with an improved, next generation product with higher clinical sensitivity overall, as well as an even broader panel. With more than 100 diagnostic targets covered by the new Unyvero ITI cartridge, we believe we have a solution with the broadest available panel for suspected implant and tissue infections and an unmatched versatility allowing the use of a wide range of routine clinical patient sample types.”

    Curetis ´ CEO Oliver Schacht, PhD, added, “A key priority for us since the IPO has been the expansion and acceleration of our product pipeline. With the successful validation and launch of the BCU product in Q2 and now the second generation ITI cartridge in Q3, we continue to deliver on key milestones of our equity story outlined at the time of our IPO.”
  7. [verwijderd] 6 september 2016 08:47
    Voor de volledigheid vanwege de datum:, Niederlande, und Holzgerlingen, Deutschland, 6. September 2016 -- Curetis N.V. (das "Unternehmen" und, zusammen mit Curetis GmbH, "Curetis"), ein Entwickler von neuartigen molekulardiagnostischen Lösungen, gab heute den erfolgreichen Abschluss der CE-IVD-Leistungsbewertungsstudie für die nächste Generation der Unyvero ITI Anwendungskartusche für Implantat- und Gewebeinfektionen bekannt.
  8. [verwijderd] 6 september 2016 15:18
    quote:

    ZAYBXC schreef op 5 september 2016 17:34:

    [...]

    Als je het goed vindt ga ik op mijn eigen advies af en wonderbaarlijk een stuk beter dan alle vier analisten maar ja ik heb ook geen dubbele agenda of wat anders.
    Gesloten op 5,59.

    Waar is Diegy toch ?
    Bedriegy is pokemons aan het vangen in kijkduin, ik moet zeggen dat gaat hem beter af dan beleggen!
  11. [verwijderd] 7 september 2016 16:38
    quote:

    Dr. Oogkloot schreef op 7 september 2016 16:36:

    En dat is gelijk te merken.. Heb een gok gewaagd op 5,95 en dit pakt tot dusver goed uit.. Misschien nog wat langer vasthouden:P
    haha dit snap ik niet, hoezo pakt het goed uit dan? Je hebt nog geen koerswinst toch? (ik heb ook gekocht op 5.95)
  15. [verwijderd] 7 september 2016 17:26
    quote:

    25GTi schreef op 7 september 2016 17:21:

    [...]
    Waar vond je deze info? Op hun website staat er niets over...
    Je zit blijkbaar dicht op het nieuws.
    Staat wel op Curetis website en donderdag 8 september speciale webcast over dit nieuws. Is dus redelijk groot nieuws.

    www.curetis.com/uploads/tx_news/20160...
  19. [verwijderd] 7 september 2016 22:04
    Curetis verwerft database Siemens
    Gepubliceerd op 7 sep 2016 om 17:33 |

    AMSTERDAM (AFN/BLOOMBERG) - Het Duitse biotechbedrijf Curetis heeft een database van Siemens verworven. Daardoor verzekerde het in Amsterdam genoteerde bedrijf zich van de kennis, patenten en commerciële rechten tot genetische resistentie tegen antibiotica van Siemens Technology Accelerator.

    Door de overname mag Curetis wereldwijd producten ontwikkelen en verkopen. Ook heeft het de mogelijkheid om licenties af te geven. Curetis maakte geen financiële details bekend.

    www.iex.nl/Nieuws/ANP-070916-213/Cure...
  20. [verwijderd] 8 september 2016 07:46
    Curetis Acquires Patents and Rights to Genetic Antibiotic Resistance and Susceptibility (GEAR) Database and Know- How from Siemens

    - Agreement gives Curetis worldwide rights to database and IP based on Next Generation Sequencing
    - GEAR significantly enhances Curetis’ leading position in the area of genetic antimicrobial resistance biomarker testing

    Amsterdam, the Netherlands, and Holzgerlingen, Germany, September 7, 2016 -- Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced the signing of an asset acquisition agreement with the Siemens Technology Accelerator GmbH (STA). Under the terms of the agreement, Curetis has acquired sole commercial rights from STA to the GEAR GEnetic Antibiotic Resistance and Susceptibility platform and database with all its content, numerous GEAR-related patents and patent applications, as well as all corresponding know- how. The deal gives Curetis sole worldwide product development and commercial rights, including the right to sublicense in the fields of human and animal diagnostics as well as food safety testing. Furthermore, Curetis has secured the sole rights to leverage the GEAR assets in collaboration with pharmaceutical companies for the development of novel antimicrobial drugs for human and animal health.

    As consideration for these assets, STA will receive an undisclosed upfront payment from Curetis. Furthermore, Curetis will make undisclosed milestone payments for products including GEAR biomarkers upon first CE IVD marking and first FDA approval (or similar regulatory clearance), respectively. Also, there will be royalty payments to STA in industry- typical percentage ranges on future products based on use of the GEAR platform or GEAR biomarkers. Further financial details were not disclosed.

    The state-of-the-art GEAR bioinformatics platform and database was developed and compiled in collaboration with two academic partners: The Institute of Clinical Molecular Biology (IKMB) at Kiel University that carried out the next generation sequencing (NGS) of bacterial isolates and the Clinical Bioinformatics Group of Saarland University headed by Prof. Dr. Andreas Keller that developed the bioinformatics platform and performed the computational analysis of 30 Terabyte of data underlying the GEAR database. GEAR allows users to assemble and annotate bacterial genomes from NGS raw data, identify genetic variations in those genomes and correlate those with the response of the respective bacterial strain to antibiotics. Currently, the GEAR database contains the entire DNA sequences as well as sensitivity data for 21 antibiotics of more than 11,000 bacterial strains isolated from patient samples across the world over the last three decades. It will allow Curetis to rapidly identify potential novel biomarkers, biomarker combinations, and algorithms predicting antibiotic resistance, as well as potential novel targets for antimicrobial drugs.

    The acquisition of the GEAR database and patent estate adds significantly to the leadership position that Curetis has established in the area of genetic antimicrobial resistance biomarker testing with its Unyvero Application Cartridges. Curetis will further expand and mine the GEAR database in collaboration with leading academic institutions as well as pharmaceutical and diagnostics companies and leverage those into commercial products on its Unyvero Molecular Diagnostics platform and beyond.

    “We are thrilled to have won in the competitive bidding process for this unique and exciting asset,” said Dr. Achim Plum, Chief Commercial Officer of Curetis. “With this platform, we are planning to build a network of strong and collaborative relationships with academics, clinicians and companies in the fields of diagnostics and pharmaceuticals alike. We will develop this repository into a valuable resource of antibiotic resistance biomarkers available to the global research community, while leveraging the proprietary nature of GEAR into our own Unyvero products and platform in the future.”

    Oliver Schacht, CEO of Curetis, added, “Since our IPO, we have diligently executed on our commercial and product development plans. At the same time, we have kept our eyes open for strategic opportunities such as the GEAR acquisition. GEAR allows us to significantly expand the scale and scope of the Unyvero platform and complement it with NGS-based knowledge. GEAR will become an engine for even more comprehensive and differentiated content of antibiotic resistance biomarkers in our Unyvero products and allow us to stay on top of the development of cutting-edge molecular diagnostic products for critical hospital infections.”

    Prof. Keller, one of the initiators of the project, highlighted the broad and unique character of GEAR: “The more than 11,000 whole bacterial genomes collected over three decades and across many countries in combination with culture-based phenotypic resistance profiles against 21 drugs enabled us to investigate multivariate genetic resistance mechanisms in a very comprehensive manner”. Prof. Keller also underlined that Curetis is a perfect partner for commercialization of tests for antibiotic resistance derived from GEAR: “We are convinced of the success of genetic antibiotic resistance tests and committed to support Curetis in their endeavor to improve care for patients suffering from bacterial infections”

    www.curetis.com/uploads/tx_news/20160...
777 Posts
Pagina: «« 1 ... 27 28 29 30 31 ... 39 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee